Phase II Study of Recombinant Interleukin la and Etoposide ......1722 IL-la and Etoposide in...
Transcript of Phase II Study of Recombinant Interleukin la and Etoposide ......1722 IL-la and Etoposide in...
Vol. 3, 1 721-1729, October /997 Clinical Cancer Research 1721
3 The abbreviations used are: OS, osteosarcoma; IL, interleukin: PR,
partial response; TNF-a, tumor necrosis factor a; NO, nitric oxide.
Phase II Study of Recombinant Interleukin la and Etoposide in
Patients with Relapsed Osteosarcoma 1
Laura L. Worth, Norman Jaffe,
Robert S. Benjamin, Nicholas E. Papadopoulos,
Shreyaskar Patel, A. Kevin Raymond,
Shu-Fang Jia, Carlos Rodriguez, Jacalyn Gano,
Mary Ann Gianan, and Eugenie S. Kleinerman2
Departments of Pediatrics IL. L. W., N. J., E. S. K.I, Cell Biology
[S-F. J., C. R., J. G., M. A. G., E. S. K.], Pathology IA. K. RI. andMedical Oncology [R. S. B., N. E. P. S. P.1, The University of Texas
M. D. Anderson Cancer Center, Houston, Texas 77030
ABSTRACT
A Phase II trial using interleukin hi (IL-la) and eto-poside for patients with relapsed osteosarcoma (OS) was
undertaken to assess the feasibility and tolerability of corn-bination therapy with biotherapy and chemotherapy. Nine
patients with histologically proven relapsed OS were treated
with IL-la immediately followed by etoposide daily for 5
days every 3 weeks. Surgical resection of lung metastasis or
peripheral tumor was performed after two or three cycles.We observed three partial responses; disease was stable inanother case. One case could not be evaluated. The sideeffects associated with combination therapy were as pre-
dicted from known side effects of the individual agents;
however, more profound neutropenia was observed. Four
patients exhibited clinical signs of capillary leak syndrome,
i.e., hypotension, edema, and weight gain. The etiology of the
capillary leak was unclear, because serum IL-la, IL-2, tu-mor necrosis factor, and nitric oxide levels could not be usedto predict which patients would develop capillary leak. His-tological analysis of tumor specimens obtained after two or
more courses of therapy showed changes consistent with a
response to a biological response modifier: peripheral fibro-
sis surrounded the metastasis with infiltration of chronic
and acute inflammatory cells. Because the response of Fe-lapsed OS to any type of salvage regimen has been poor, we
interpret the clinical response of this therapy as good. How-ever, the significant side effects associated with this therapy
must also be taken into consideration before deciding to use
Received 4/30/97: revised 7/1/97: accepted 7/8/97.The costs of publication of this article were defrayed in part by thepayment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
I Supported in part by Grants CA-l7772, CA-42992, and CA-66632.
Also supported by a grant from the Gillson-Longenbaugh Foundation
(to E. S. K.).2 To whom requests for reprints should be addressed. at Department of
Cell Biology, Box 173, The University ofTexas M. D. Anderson CancerCenter, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713)
792-81 10: Fax: (713) 792-8747.
this combination therapy. It is unfortunate that the study
was stopped early due to halted production of IL-la. If this
agent is again manufactured for clinical use, we conclude
that additional evaluation in patients with relapsed OS iswarranted.
INTRODUCTION
The majority of patients with OS� have subclinical pulmo-
nary micrometastases at the time of initial presentation and
diagnosis. Surgical resection of the primary tumor coupled with
intensive adjuvant chemotherapy has improved the metastasis-
free survival rate from less than 20% at 2 years to 60% at S years
( 1-3). However, 30-40% of these patients still die of pulmo-
nary metastases that are resistant to conventional therapy (2-4).
The majority of patients experience a relapse within the first 2
years, either while receiving adjuvant chemotherapy or shortly
after the completion of chemotherapy. The prognosis for these
patients is poor. Although the metastases can be removed by
surgery, 70-85% will recur within 1 year (2-4). Several che-
motherapeutic agents, different from those used in the initial
therapy, are being studied in an attempt to develop more effec-
tive therapy.
One agent that has been studied is etoposide, an intracel-
lular poison that acts by stabilizing the cleavable complex
between topoisomerase II and DNA. The drug-topoisomerase II
DNA complex formation initiates a series of intracellular events
culminating in the death of the cell (5). The experience with
etoposide used as a single agent in relapsed OS is limited. A
Pediatric Oncology Group study (6) analyzed the effect of
etoposide when ISO mg/m2/day were given IV for 3 days every
3 weeks. Of the 1 1 patients studied, I PR and 1 minor response
were observed. Consequently, etoposide as a single agent is not
considered active against relapsed OS.
IL-l is primarily a monocyte/macrophage product pro-
duced in response to infection, injury, or immune challenge.
Among its numerous biological activities are inducing other
cytokines [e.g., IL-2, IL-6, colony-stimulating factors, TNF, and
intracellular adhesion molecules (7-9)] and activating T and B
lymphocytes (10-12). It also enhances the ability of lympho-
cytes to bind and kill tumor cells (13). In melanoma cells, a
synergistic interaction between IL- I a and etoposide has been
reported (14).
Recent studies (IS, 16) demonstrated that IL-la enhanced
the in vitro cytotoxicity of etoposide. In three different human
OS cell lines with relative resistance to etoposide, use of IL- 1a
increased the cytostatic activity of etoposide from 9% to 70%.
The synergistic activity was only demonstrated when IL-la
incubation preceded or coincided with etoposide. When etopo-
on May 3, 2021. © 1997 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from
1722 IL-la and Etoposide in Relapsed Osteosarcoma
entry.
Table I Patient characteristics
Metastasis
Zubrod Pathological Primary at PriorPatient score Age Race” Sex disease subtype disease site diagnosis chemotherapy” Responsec
1 1 15 H F Fibroblastic Femur + ifx Mtx
CDDP Ad/iaPR
2 1 17 W M Osteoblastic Femur - ifx MtxCDDP Adriaetop thio
hycamp
Inevaluable
3 0 32 W F Dedifferentiated
paraostealFemur - ifx CDDP
Adria TaxolSD
4 0 17 W F Chondroblastic Femur - ifx Mtx
CDDP Adriableo CytActD Etop
Mixed
5 2 18 B F Osteoblastic Tibia - ifx Mtx
CDDP AdriaPD
6 1 3 1 H M Chondroblastic Hard palate - ifx Mtx
CDDP Ad/iaTaxol
Mixed
7 0 43 A F Fibroblastic Femur - ifx MtxCDDP AdriaTaxol DTIC
PR
8 0 14 H M Osteoblastic Femur - ifx Mtx
CDDP AdriaPR
9 0 19 W M Not specified Femur - ifx Mtx
CDDP Ad/iacarbo hycamp
PD
white; B, black; A, Asian.“ H, Hispanic; W,I’ ifx, ifosfamide; Mtx, methotrexate; CDDP, cisplatin; Adria, doxorubicin; etop, etoposide; thio, thioguanine; hycamp, hycamptamine; bleo,
bleomycin; taxol, paclitaxel; cyt, cyclophosphamide; ActD, dactinomycin; DTIC, dacarbazine: carbo, carboplatin.
‘ PR, partial response; SD. stable disease; PD, progressive disease.
side incubation preceded IL-la, no synergy was seen (15). This
clinical trial study was undertaken to assess the feasibility of
combination IL-la and etoposide therapy and its efficacy in
patients with relapsed OS.
PATIENTS AND METHODS
The characteristics of the patients in this trial are summa-
rized in Table I . Nine patients were enrolled in this study
between April and September 1994. The median age of the S
female and four male patients was 18 years. All patients had
resection of the primary tumor and received prior therapy with
ifosfamide, cisplatin, and doxorubicin; all but 1 (patient 3) also
received high-dose methotrexate. These four drugs are the most
effective agents currently in use against OS. Six patients also
received additional chemotherapeutic agents, including etopo-
side, carboplatin, dacarbazine, bleomycin, cyclophosphamide,
thioguanine, paclitaxel, and hycamptamine. OS recurred in the
lung (eight cases), primary site (three cases), mediastinum (one
case), humerus (one case), and paraspinal area (one case). Two
patients (patients 4 and 6) received prior radiotherapy. None of
the patients received any prior immunotherapy.
Eligibility criteria included the following: (a) patients from
S to 70 years of age with histologically proven OS in whom
standard therapy was not effective; (b) measurable disease; (c)
an estimated life span � I 2 weeks and a Zubrod performance
status of 0-2; and (d) no chemotherapy, immunotherapy, hor-
monal therapy, or radiation therapy within 3 weeks of study
Patients were excluded if they had any serious intercurrent
illness, had received more than one biological response modi-
fier, or had significant cardiovascular disease. All patients gave
written informed consent to participate in the study in accord-
ance with established guidelines from the Surveillance Commit-
tee at M. D. Anderson Cancer Center.
Drugs. Recombinant IL-la was supplied by the Drug
Management and Authorization Section, Cancer Therapy and
Evaluation Program, National Cancer Institute. Each lOO-p.g
vial of sterile, white, preservative-free, lyophilized powder also
contained 10 p� of human serum albumin. The compound was
reconstituted in S ml of 0.9% sodium chloride for injection,
USP, and was stable 24 h after reconstitution.
Treatment Plan. IL- la (0. 1 p.glkg/day) was adminis-
tered s.c., followed immediately by iv. administration of
etoposide (100 mg/m2) via central venous catheter over 3 h.
Patient intake and output were strictly monitored. In the
hemodynamically stable patient, vital signs were measured
hourly for 3 h and then every 4 h. In patients experiencing
hypotension or other side effects, vital signs were monitored
every 5-15 mm until the patient was hemodynamically sta-
ble. Hemograms were monitored twice weekly; chemistries
(i.e., electrolytes and liver function tests) and urinalysis were
monitored weekly. IL-Ia and etoposide were given daily for
S days every 3 weeks. Patients were monitored with the
appropriate X-ray studies prior to each course of treatment.
Surgical resection of lung metastases or peripheral tumors
was performed after two or three courses.
on May 3, 2021. © 1997 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from
Clinical Cancer Research 1723
Efficacy. Disease was assessed after two courses using
standard response criteria. Disappearance of all evidence of a
tumor for at least one cycle (4 weeks) with resolution of all
symptoms associated with the tumor constituted complete re-
sponse. A greater than 50% decrease in the sum of the diameters
of all measured lesions for more than one cycle (4 weeks) and
no new lesions or increase in size of any lesion constituted a PR.
Minor response was defined by a less than 50% decrease in the
diameters of all measured lesions for more than one cycle. A
greater than 25% increase in the sum of the diameters of
measurable lesions or estimated nonmeasurable lesions was
considered progressive disease. Responses based on tumor ne-
crosis were defined as �90% necrosis, complete response;
60-89% necrosis, PR; and < 60% necrosis, stable disease.
Every attempt was made to give three courses of treatment and
evaluate tumor response histologically.
Cytokine Analysis. Serial blood samples were collected
at different times during the first course of combination therapy
in standard hematology collection tubes (plasma), stored at 4#{176}C,
and processed within 1-2 h of collection. Aliquots of plasma
were stored at -70#{176}C.
Serum IL-la, IL-2, and TNF-a levels were measured using
a solid-phase sandwich ELISA kit [Biotrak, obtained from
Amersham International, Poole, United Kingdom (for IL-la) or
from Biosource International, Camarillo, CA (for IL-2 and
TNF-a)] following manufacturers’ recommendations.
NO produced by the body is rapidly oxidized to nitrate and
nitrite. These products were reduced to nitric oxide in vanadium
chloride and measured in a nitric oxide chemiluminescence
analyzer (Sievers Instruments, Boulder, CO). Values were de-
termined by comparison against a standard curve.
RESULTS
Unfortunately, the study had to be closed prematurely
when IL-i-a was no longer available for clinical use due to
supply problems.
Clinical Toxic Side Effects. The clinical side effects
associated with IL-la and etoposide therapy are outlined in
Table 2. One patient (patient 2) had a severe reaction after
receiving the first dose of the first course of IL- la and etopo-
side. He developed respiratory distress with tachypnea, an in-
crease in oxygen requirement, and facial and upper extremity
edema. His symptoms resolved with furosemide, diphenhydra-
mine, and decadron. The severity of the reaction caused the
patient to be taken off the protocol. Thus, only the data from the
remaining eight patients are analyzed. A total of 35 courses of
IL-la and etoposide (range, 2-9; median, 4; and mean, 4.4)
were given to these eight patients. The side effects and toxicities
of the etoposide and IL- la together were as predicted from the
known side effects of the individual agents. More than 75% of
the courses were associated with fever, chills, vomiting, head-
ache, fatigue, myalgias, and alopecia. More than 90% (32 of 35)
of the courses were associated with hypotension. More than
60% of the patients who experienced hypotension required
intervention for the condition. Most cases of hypotension were
managed with fluid therapy; however, two cases required blood
pressure support with dopamine to maintain systolic blood pres-
sures greater than 80 mm Hg.
Table 2 Toxicities asso ciated wit h IL- Ia and etoposide therapy
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Anemia 0 9 24 2
Thrombocytopenia 1 2 3 24
Neutropenia 0 0 0 35
Infection 16 0 7 1
Hypotension 13 17 2 0
Chills 0 26 8 0
Drug fever 2 28 5 0
Fatigue 5 10 8 0
Myalgia 4 15 0 0
Local skin reaction 9 1 0 0
Headache 4 20 4 N/A
Nausea 6 14 1 N/A
Vomiting 8 19 6 0
Diarrhea 2 4 0 0
Anorexia 9 17 3 0
Alopecia 0 32 N/A N/A
Stomatitis 7 8 3 0
Capillary leak syndrome 0 5 0 0
Creatinine elevation 1 1 0 0
Bilirubin elevation 0 4 4 3
Aspartate 5 2 3 0
aminotransferase
elevation
All courses of etoposide and IL-la were associated with
anemia of varying grades. Nine courses produced grade 2 ane-
mia; patients received 0-4 units of packed RBCs. In the 24
courses associated with grade 3 anemia, one-third did not re-
quire transfusions. The other courses required transfusion with
1-7 units of packed RBCs. Only two courses were associated
with grade 4 anemia; 4 and 6 units of packed RBCs were
transfused under these conditions. Two-thirds of the courses of
IL-la and etoposide produced thrombocytopenia with platelet
counts less than 25,000/mm3 (grade 4). Two-thirds of these
courses required platelet transfusions (4-60 units). All 35
courses of chemotherapy were associated with lowered absolute
granulocyte counts with nadirs less than 0.5/mm3. One patient
(patient 1) had an etoposide dose reduction of 25% for the
second course and of 50% for the third course secondary to
prolonged neutropenia and severe mucositis. The dose was
raised back to 100% for subsequent courses.
A significant therapy complication was fever and neutro-
penia that required hospitalization in 1 6 of the 35 courses. These
patients received iv. antibiotics until blood cultures were neg-
ative for at least 48 h, fever defervesced, and neutrophil counts
began to rise. In an additional 20% of the courses, the neutro-
penia was associated with blood cultures positive for Kiebsiella
pneumonia (two cases), Escherichia coli (two cases), Proteus
inirabilis (one case), Brahhamella catarrhalis (one case), Staph-
ylococcus hominis (one case), and a-hemolytic streptococcus
(one case). One patient in this group delayed seeking medical
attention despite known fever and neutropenia. Septic shock was
caused by Escherichia co/i and a-hemolytic streptococcus, re-
sulting in the death of the patient.
Less frequent complications included stomatitis, diarrhea,
and elevations in levels of serum bilirubin, aspartate aminotrans-
ferase, and creatinine. In 25% of the courses, local reactions at
the site of injection were noted.
on May 3, 2021. © 1997 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from
1724 IL-la and Etoposide in Relapsed Osteosarcoma
-0---
-D-
U
-G--
-I-
2
3
4
S
6
7
8
9
30
20
10
0
Time (hours)
-�0--- 2
2000
1000
0
-1000#{149}
Fig. 2 Plasma levels of TNF-a following the
administration of IL-la and etoposide. Blood
samples were collected from patients 2-9 at
various times after etoposide and IL-la admin-
istration. Plasma was separated, frozen at
-70#{176}C. and subsequently assayed for TNF-a.
S
-D---
U
A
-0--
S
K
3
4
S
6
7
8
9
0 2 4 24 72 120
Capillary leak syndrome was associated with five courses
of chemotherapy in four patients. These patients exhibited
edema and weight gain of less than 10 pounds. These symptoms
resolved readily following the administration of furosemide.
Plasma Cytokines Induced following IL-la and Etopo-
side Administration. We obtained and analyzed plasma from
eight patients during their first course of treatment. Serum IL-la
Time (hours)
was not detectable in any patient prior to s.c. therapy. Beginning
1 h after treatment, IL-la levels were detectable; they peaked
3-4 h after administration and returned to baseline by 24 h (Fig.
1). Because IL-la has been shown to induce the production of
TNF-a, we also quantified changes in levels of plasma TNF-a.
As shown in Fig. 2, there was no consistent increase in the levels
of plasma TNF-a in any of the patients. Indeed, decreased
E
z
c)
Fig. 1 Plasma IL-la levels following the admin-
istration of IL-la and etoposide. Blood samples
were collected from patients 2-9 at various times
after etoposide and IL- la administration. Plasma
was separated, frozen at -70#{176}C, and subsequently
assayed for IL-la.
on May 3, 2021. © 1997 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from
200
175
150
125
100
-0--- 2
S 3
-a--- �. S
-fr.-- 6
-0--- 7
-1-- 8
K 9
75
50
25
0 2 4 24 72 96
Time (hours)
-0--- 2
S 3
0 2 4 24 72 96
Clinical Cancer Research 1725
Fig. 3 Plasma levels of IL-2 following the ad-
ministration of IL-la and etoposide. Blood sam-
ples were collected from patients 2-9 at various
times after etoposide and IL- la administration.
Plasma was fractionated, separated, frozen at-70#{176}C,and subsequently assayed for IL-2. Notethat plasma samples from patient 2 were col-lected during an episode of capillary leak.
0U
z
30
20
10
0
Fig. 4 Plasma levels of NO following the ad-ministration of IL-la and etoposide. Blood sam-
ples were collected from patients 2-9 at various
times after etoposide and IL-la administration.
Plasma was separated, frozen at - 70#{176}C,and sub-sequently assayed for NO. Note that plasma sam-
ples from patient 2 were collected during an epi-
sode of capillary leak.
Time (hours)
plasma TNF-a levels were seen in five of eight patients follow-
ing combination therapy.
The etiology underlying the capillary leak syndrome seen
in four patients was also examined. IL-2 and NO have been
associated with hypotension and peripheral capillary leak syn-
drome. Therefore, patient plasma samples were also examined
for levels of IL-2 and NO. Figs. 3 and 4 illustrate that there was
no correlation between plasma IL-2 or NO levels and the de-
velopment of hypotension and edema following IL-la and
etoposide therapy. Significant increases in plasma IL-2 were
only seen in patients 3 and 5. Capillary leak syndrome did not
develop in patient 3 but was apparent in patients 2, 4, and 5.
on May 3, 2021. © 1997 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from
4 R�’J1 6894
1726 IL-la and Etoposide in Relapsed Osteosarcoma
Fig. S Chest radiographs ofpatient 1 . Studies were obtainedprior to (left panel) and after(right panel) two courses of eto-poside and IL- 1a. An increase is
seen in the metastasis in theright upper lobe. Decreases areseen in the size of the left mid-dle and upper lobe metastases.No new disease is seen.
Clinical Response. As mentioned earlier, an adverse re-
action after the initial dose of IL-la and etoposide prevented
one patient (patient 2) from being included in our evaluation. Of
the remaining eight patients, disease in three patients responded
partially to therapy. These patients received five to nine courses,
and their PR lasted for 6-8 months.
Patient 1 presented with bilateral pulmonary metastases.
After the patient received two courses of combination therapy,
a chest X-ray showed enlargement of the pulmonary mass on the
right and decreases in the size of several lesions on the left (Fig.
5). Initially, this case was classified as a mixed response. A
thoracotomy was performed after the second course of treatment
because of the confusing clinical picture and what was pre-
sumed to be an enlarging mass in the right lung. The operation
revealed a cavitated spherical cyst filled with fluid. Histologi-
cally the cystic mass (Fig. 6) was composed of cellular debris,
inflammatory cells, and granulation tissue, with small pockets of
viable tumor cells only at the peripheral rim of the cyst. There-
fore, we concluded that the radiographic expansion of the mass
was not due to tumor growth but rather was secondary to
collection of fluid and inflammatory elements within the cystic
lesion. In view of the shrinking lesions in the left lung and the
necrotic tumor cells in the right lesion, we classified the case as
a PR. This patient received two additional courses of combined
therapy, and the lesions in the left lung were surgically resected.
Here too, the histological examination revealed intralesional
hemorrhage, fragments of dishesive tumor with some viable
tumor cells, and moderate infiltration with both acute and
chronic inflammatory cells. The findings are not typical of those
seen with chemotherapy in which the metastatic lesion has
central necrosis surrounded by a rim of viable tumor cells
growing into compressed normal lung tissue ( I 7).
The second patient (patient 7) to achieve a PR underwent
surgical resection of nodules in the right lung after three courses
oftherapy. On the basis of results from radiographic studies, this
patient’s disease was classified as stable. Histological examina-
tion of the tumor mass showed greater than 80% necrosis. The
majority of what were interpreted initially as “viable” cells were
shown by immunohistochemical studies to be inflammatory in
origin. Consequently, the case was also classified as a PR based
on histological examination.
The final patient in the PR category (patient 8) also had
bilateral pulmonary metastases; one lesion was almost corn-
pletely resolved, and the others decreased in size with treatment.
This patient had a single surgical excision of the pulmonary
metastases after three courses of treatment. The remaining mass
showed liquefaction and necrosis. Some cell dropout suggestive
of a response to a therapeutic agent was noted. However, there
was cautery damage to the tissue, which made the interpretation
less conclusive.
Although mixed response is not a traditional category, parts
of tumors in two patients had dramatic responses. Patient 6 had
OS of the hard palate. At this patient’s entry into the study, the
tumor mass was pushing the tongue posteriorly, partially ob-
structing the aerodigestive tract and requiring tracheostomy and
gastrostomy. After three courses of chemotherapy, the intraoral
portion of the tumor had regressed sufficiently to allow the
patient to speak more clearly and swallow. On radiographic
studies, the tumor progressed anteriorly, compromising the optic
chiasm and resulting in progressive loss of vision in one eye.
The other patient in this category (patient 4) had metastatic
disease to the lung as well as to the humerus and surrounding
soft tissue. She underwent surgical resection after two courses of
IL- I a and etoposide to assess response to therapy; the decrease
in pulmonary disease was accompanied by increased disease
invasion of soft tissue around the humerus. Pathological speci-
mens of the pulmonary nodules obtained after two courses of
therapy contained more than 80% necrosis. The humeral in-
tramedullary disease had >90% necrosis; however, the ex-
tramedullary, soft tissue component only exhibited 60% necro-
sis. In this case too, one area of the tumor responded
dramatically to therapy, whereas in another area the response
was less impressive.
Patient 3, with previous rapidly progressive pulmonary
disease, exhibited stable disease when treated with IL-la and
etoposide.
on May 3, 2021. © 1997 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from
�. .� -- . . � :�
�
Clinical Cancer Research 1727
Fig. 6 Histological sections of
OS lung metastasis removed at-ter therapy with etoposide andIL-la in patient 1 . A, residual
tumor (T between brackets) and
underlying fibrosis (F) form athin rim at the interface between
normal lung (NL) and central
cystic cavity (CC; H&E; mag-nification, X40). B, “residualtumor” is made up of a heterog-enous mixture of elements. Thetumor itself, with the accompa-nying osseous matrix (solid ar-
rows), is composed of appar-ently unaffected neoplastic cellsand cells with significant degen-erative cytological changes, aswell as cell dropout (hollow ar-
rowheads). There is a mixed in-
flammatory infiltrate scattered
diffusely throughout the lesion
(Infi), and it includes lympho-cytes, plasma cells, histiocytes
(some hemosiderin laden), and
polymorphonuclear cells (H&E;magnification, x 100).
Two patients had progressive disease. Brain metastases
developed in one patient (patient 5) after the second course of
chemotherapy. This patient was removed from the protocol.
Lung disease developed in the other patient (patient 9) after the
: � �
‘I�4 �
‘C’s_ . �
�
�.J
ja.. 4�#{149} .r
� � �1
.,±, 4�?
Q� �
�A �
‘.
-�. ‘�‘1’..��;- .F�f1w ‘ � � ,
,-. � S� , ‘ ‘�
� .� �
first course, but this patient received a second course, because
the disease had responded poorly to previous therapies; there
were essentially no other treatment modalities available. After
the second course, radiographic studies indicated some of the
on May 3, 2021. © 1997 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from
1728 IL-la and Etoposide in Relapsed Osteosarcoma
pulmonary nodules responded to therapy with necrosis and
liquefaction, whereas other areas did not. Low pulmonary
reserve precluded this patient from being a candidate for
thoractomy.
DISCUSSION
Although we were unable to complete this Phase II trial
because IL-la became unavailable, we demonstrated that the
biotherapy-chemotherapy combination is feasible and tolerable.
The side effects associated with the study were predicted from
the known side effects of each agent. However, the profound
neutropenia was greater than that experienced when etoposide
was used as a single agent. Fever and neutropenia were signif-
icant side effects requiring hospitalization of the affected pa-
tients. Sixteen of the 35 courses were associated with fever,
neutropenia, and blood cultures negative for bacteria. Seven
courses (20%) were associated with positive blood cultures in
addition to neutropenia. The profound neutropenia may be ex-
plained by the higher median daily area under the curve and
lower clearance rates quantified in patients receiving combina-
tion IL-Ia and etoposide compared with those values reported
when etoposide is administered alone (18). Alternatively, the
synergistic interaction that caused increased tumor killing of
cells may also have caused increased killing of bone marrow
cells. Only one patient required reduction in etoposide dose (for
two courses); it was restored to 100% for the remainder of the
courses.
Four patients in five courses of therapy had symptoms
suggestive of peripheral capillary leak syndrome (hypotension,
edema, and weight gain). Serum levels ofthe proteins associated
with this syndrome (IL-l , IL-2, and TNF-a) and NO were not
helpful in predicting which patients would develop capillary
leak. The factors involved in the development of this syndrome
are still unclear.
A difficult problem in analyzing tumor response to a bio-
logical response modifier is measuring the clinical response to
the therapy. In situations in which cytokines are administered or
their release is stimulated, an inflammatory reaction can be
initiated. By conventional radiography, this inflammatory prod-
ess can appear as an enlarging tumor mass and be interpreted as
worsening disease. Consequently, evaluating the results of
chemotherapy plus biological response modifiers against meta-
static lung disease by use of a chest radiograph may not truly
represent what is happening on the cellular level. In several
patients, an inflammatory response was initiated that resulted in
fluid accumulation either as a cystic mass surrounding the
metastatic nodules or actually replacing the disease. If a lesion
is partially filled with fluid, an air-fluid level can be appreciated
and may differentiate such a mass from an enlarging metastasis.
When results of therapy were not clear, surgery was performed
without waiting for the third course of chemotherapy to be
completed. We correlated the histological characteristics of
these enlarging metastatic lesions with their appearance on
nuclear magnetic imaging scans to better interpret the effects of
therapy.
For most patients, the time needed to recover from thoracic
surgery was usually 2 weeks. Consequently, the time interval
between courses of etoposide and IL-la was 6 to 8 weeks. Two
patients had two surgical procedures between courses of chem-
otherapy (sequential thoracotomies and thoracotomy followed
by hemipelvectomy). For these patients, the time between
courses of chemotherapy when separated by two surgical pro-
cedures approached 3.5 months. During this interval without
therapy, it was not uncommon for the tumor that had been
responding to chemotherapy to begin to grow again.
Because the response of relapsed OS to any type of salvage
regimen has been poor, we interpreted the clinical response to
this therapy as good, with three PRs and one case of stable
disease in eight patients. All four patients had previously failed
a number of salvage regimens in addition to their front-line
chemotherapy. If the assessment of the response to therapy were
determined by more conventional methods, using only radio-
graphic evidence, than only one patient would be considered to
have had a PR. Judged by traditional criteria, this therapy would
have the same overall outcome as in the Phase II study evalu-
ating etoposide as a single agent (6). However, biological re-
sponse modifiers, such as IL-la, act by stimulating the immune
system, enhancing the cytotoxic activity of agents, and inhibit-
ing angiogenesis (19). Consequently, determining the response
rate using only radiographic evidence when there is a mass
effect from inflammation and hemorrhage could result in un-
derestimation of response and the possible elimination of a
potentially useful combination therapy. Under strict criteria, the
mixed response category is considered progressive disease.
However, it was a distinct category in this study because parts
of two patients’ tumors showed response to therapy. In the
patient with metastatic disease to the humerus that extended into
the adjacent soft tissue, the intramedullary disease showed
greater than 90% necrosis histologically. She had no therapy for
4 weeks before beginning IL-la and etoposide; thus this necro-
sis is unlikely to have been the result of prior therapy. The soft
tissue disease failed to respond to therapy. For the patient with
OS of the hard palate, tumor regression restored the ability to
speak more clearly and eat again; this was a welcome relief and
a dramatic response.
Halted production of IL-la caused this study to be stopped
prematurely. If this agent is again manufactured for clinical use,
we conclude that its further evaluation in patients with relapsed
OS is warranted. Although some side effects were significant
and need to be taken into consideration, the rate of disease
response in this study of combined biotherapy and chemother-
apy makes this approach promising.
REFERENCES
I . Jaffe, N. Chemotherapy in osteosarcoma: advances and controver-
sies. In: F. M. Muggia (ed), Experimental and Clinical Progress inCancer Chemotherapy, pp. 223-233. Boston: Martinus Nijhoff Publish-
ers, 1986.
2. Link, M. P., Goorin, A. M., Miser, A. W.. Green, A. A., Pratt, C. B.,Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick,J. A., Ayala, A. G., Shuster, J. J., Abelson, U. T., Simone, J. V., andVietti, T. J. The effect of adjuvant chemotherapy on relapse-free sur-vival in patients with osteosarcoma of the extremity. N. Engl. J. Med.,314: 1600-1606, 1986.
3. Eilber, F., Giuliano, A., Eckardt, J., Patterson, K., Moseley, S., andGoodnight, J. Adjuvant chemotherapy for osteosarcoma: a randomized
prospective trial. J. Clin. Oncol., 5: 21-26, 1987.
on May 3, 2021. © 1997 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from
Clinical Cancer Research 1729
4. Goorin, A. M., Perez-Atayde, A., Gebhardt, M., Anderson, J. W.,
Wilkinson, R. H., Delorey, M. J., Watts, H., Link, M., Jaffe, N., and
Frei, E. Weekly high-dose methotrexate and doxorubicin for osteosar-
coma: the Dana-Farber Cancer Institute/The Children’s Hospital-
Study III. J. Clin. Oncol., 5: 1 178-1 184, 1987.
5. Ross, W., Rowe, T., Glisson, B., Yalowich, J., and Liu, L. Role of
topoisomerase II in mediating epipodophyllotoxin-induced DNA cleav-
age. Cancer Res., 44: 5857-5860, 1984.
6. Kung, F., Hayes, F. A., Krischer, J., Mahoney, D., Jr., Leventhal, B.,Brodeur, G., Berry, D. H., Dubowy, R., and Toledano, S. Clinical trialof etoposide (VP-16) in children with recurrent malignant solid tumors:a Phase II study from the Pediatric Oncology Group. Invest. New Drugs,
6: 31-36, 1988.
7. Le, J., and Vilcek, J. Tumor necrosis factor and interleukin- 1 : cyto-
kines with multiple overlapping biological activities. Lab. Invest., 56:
234-248, 1987.
8. Ochoa, A. C., Gromo, G., Alter, B. J., Sondel, P. M., and Bach, F. H.
Long-term growth of lymphokine-activated killer (LAK) cells: role of
anti-CD3, beta-ILl, and interferon-gamma and -beta. J. Immunol., 138:
2728-2733, 1987.
9. Belardelli, F., Proietti, E., Ciolli, V., Sestili, P., Carpinelli, G., Divito,M., Ferretti, A., Woodrow, D., Boraschi, D., and Podo, F. Interleukin-143 induces tumor necrosis and early morphologic and metabolicchanges in transplantable mouse tumors: similarities with the anti-tumoreffect oftumor necrosis factor a or �3. Int. J. Cancer, 44: 1 16-123, 1989.
10. Farran, W., Mizel, S., and Farran, J. Participation of lymphocyte
activation factor (IL-l) in the induction of cytotoxic T-cell responses.
J. Immunol., 124: 1371-1377, 1980.
1 1. Dower, S. K., Kronheim, S. R., March, C. J., Conlon, P. J., Hopp,
T. P., Gillis, S., and Urdal, D. L. Detection and characterization of high
affinity plasma membrane receptors for human interleukin I . J. Exp.
Med., 162: 501-515, 1985.
12. Dinarello, C. A. Biology of interleukin 1. FASEB J.. 2: 108-1 15.
1988.
13. Oppenheim, J. J., Kovacs, E. J., and Matsushima, K. There is more
than one interleukin-l . Immunology, 7: 45-56, 1986.
14. Usui, N., Mimnaugh, E. G., and Sinha, B. K. Synergistic antitumor
activity of etoposide and human interleukin-la against human mela-
noma cells. J. Natl. Cancer Inst., 81: 1904-1909, 1989.
15. Jia, S-F., Zwelling, L. A., and Kleinerman, E. S. The synergisticeffect of IL-l and VP-l6 against osteosarcoma cells. Proc. Am. Assoc.
Cancer Res., 32: 227, 1991.
16. Jia, S-F., Zwelling, L. A., McWatters, A., An, T., and Kleiner-
man, E. S. Interleukin-l-a increases the cytotoxic activity of etopo-
side against human osteosarcoma cells. J. Exp. Ther. Oncol., in press.
1997.
17. Kleinerman, E. S., Raymond, A. K., Bucana, C. D., Jaffe, N.,
Harris, M. B., Krakoff, E. H., Benjamin, R., and Fidler, I. J. Unique
histological changes in lung metastases of osteosarcoma patients fol-
lowing therapy with liposomal muramyl tripeptide (CGP l9835A lipid).
Cancer Immunol. Immunother., 34: 21 1-220. 1992.
18. Soefje, S. A., Madden, T., Herzog. C., Jaffe, N., Gano, J. B., and
Kleinerman, E. S. The effect of IL- Ia on etoposide pharmacokinetics in
patients with relapsed metastatic osteosarcoma. Pharmacotherapy, 15:
375, 1995.
19. Potvin, F., Petitcler, E., Marceau, F.. and Poubelle, P. E. Mech-anism of action of antimalarials in inflammation: induction of
apoptosis in human endothelial cells. J. Immunol.. /58: 1872-1879,
1997.
on May 3, 2021. © 1997 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from
1997;3:1721-1729. Clin Cancer Res L L Worth, N Jaffe, R S Benjamin, et al. in patients with relapsed osteosarcoma.Phase II study of recombinant interleukin 1alpha and etoposide
Updated version
http://clincancerres.aacrjournals.org/content/3/10/1721
Access the most recent version of this article at:
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/3/10/1721To request permission to re-use all or part of this article, use this link
on May 3, 2021. © 1997 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from